Article Text

Download PDFPDF
Counterpoint: stenting for idiopathic intracranial hypertension should be trialed

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Twitter @CPDerdeyn

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests Consulting (Data and Safety Monitoring Committee): Silkroad (NITE trial); Penumbra (Thunder Trial); NoNO (Escape NEXT, Frontier trials). Equity (Pulse Therapeutics - Stock Options).

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles